Michael Heuser

Ernst Grube Str. 40
Halle, NI 06120, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 295 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer
Published: June 16, 2026

A Clinically Applicable Unmixing Approach for Spectral MRD Detection in AML.

A Clinically Applicable Unmixing Approach for Spectral MRD Detection in AML.

Journal: Cancers
Published: June 02, 2026

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Journal: Haematologica
Published: April 23, 2026

Heat exhaustion, domestic heat exposure and socioeconomic disparities among older adults: a cross-sectional mediation analysis from Germany.

Heat exhaustion, domestic heat exposure and socioeconomic disparities among older adults: a cross-sectional mediation analysis from Germany.

Journal: International journal for equity in health
Published: March 24, 2026

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Machine learning provides individualized prediction of outcomes after first complete remission without allo-HSCT consolidation in adult acute myeloid leukemia-A HARMONY study.

Journal: HemaSphere
Published: February 23, 2026

Guideline development for MRD diagnostics in AML as a blueprint for solid tumors

Guideline development for MRD diagnostics in AML as a blueprint for solid tumors

Journal: Pathologie (Heidelberg, Germany)
Published: February 21, 2026

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Journal: Leukemia
Published: February 08, 2026

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.

A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.

Journal: British journal of haematology
Published: February 04, 2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Journal: Blood
Published: February 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Journal: Blood
Published: February 04, 2026
Showing 1-12 of 295

Last Updated: 09/26/2026